Heartflow stock jumps 16% as AI cardiac diagnostics revenue soars 48% and guidance rises
6 Sources
[1]
Why is Heartflow stock surging today? By Investing.com
Investing.com -- Heartflow stock surged 16.1% in after-hours trading to reach $36 after the AI-powered cardiac diagnostics company delivered a second-quarter earnings report that far outpaced Wall Street's expectations on every key metric. The adjusted loss per share came in at -$0.07, beating the consensus estimate of -$0.19 by $0.12, while quarterly revenue of $64.1 million represented a 48% jump from the same period a year ago, with domestic revenue alone climbing 51% year-over-year to $59.6 million. Compounding the earnings beat, management raised its full-year 2026 revenue guidance to a range of $246 million to $250 million -- a meaningful step up from the prior outlook set after a strong first quarter -- signaling growing confidence in the continued adoption of its Plaque Analysis platform and core FFRCT business. This marks the second consecutive quarter in which Heartflow has beaten estimates and lifted guidance, a pattern that has materially strengthened investor conviction. On the insider front, CEO John Farquhar sold approximately 22,562 shares on August 10 under a pre-scheduled Rule 10b5-1 plan -- a routine, non-discretionary transaction that the market largely set aside in light of the earnings strength. The broader U.S. equity market provided virtually no tailwind on the day, with the S&P 500 adding just 0.05%, the Dow Jones edging up 0.04%, and the NASDAQ gaining 0.08% -- underscoring that today's sharp move in HTFL was almost entirely a company-specific event. Heartflow's key competitor in the AI cardiac space, Cleerly -- against whom Heartflow filed a patent infringement suit earlier this year -- did not release any material news today that contributed to the move. The combination of a substantial earnings beat, accelerating revenue growth, and a raised full-year outlook delivered precisely the kind of positive surprise that can trigger outsized after-hours moves in a high-growth medical technology name, propelling HTFL well above its session-day high of $31.72 and back toward the upper portion of its 52-week range of $20.13 to $41.22. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
[2]
Heartflow Shares Jump Pre-Bell After Q2 Loss Narrows Amid Soaring Revenue, FY26 Sales Guidance Raised
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.
[3]
Heartflow Q2 Loss Narrows, Revenue Rises; Ups Guidance
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.
[4]
Earnings Flash (HTFL) Heartflow, Inc. Reports Q2 Revenue $64.1M, vs. FactSet Est of $56.6M
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.
[5]
Earnings Flash (HTFL) Heartflow, Inc. Posts Q2 Adjusted Loss $0.07 per Share, vs. FactSet Est of $-0.13
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.
[6]
(HTFL) Heartflow Expects 2026 Revenue Range $246M-$250M, vs. FactSet Est of $230.1M
HeartFlow Inc. is a commercial-stage medical technology company that has pioneered the use of software and artificial intelligence (AI) to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD). The Company’s novel HeartFlow Platform uses AI and advanced computational fluid dynamics to create a personalized three-dimensional (3D) model of a patient’s heart based on a single coronary computed tomography angiography (CCTA). Its AI-driven platform includes Roadmap Analysis, FFRCT Analysis and Plaque Analysis. The HeartFlow FFRCT Analysis and Plaque Analysis software assists physicians in diagnosing, managing and delivering precision care to patients with CAD. The RoadMap Analysis offers a highly intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review.
Share
Copy Link
Heartflow stock surged 16.1% in after-hours trading after the AI-powered diagnostics company posted Q2 revenue of $64.1 million, up 48% year-over-year, crushing Wall Street expectations. The medical technology company raised its full-year 2026 revenue guidance to $246-250 million, signaling strong adoption of its coronary artery disease platform.
Heartflow Beats Wall Street Expectations with Strong Q2 Earnings
Heartflow stock climbed 16.1% in after-hours trading to reach $36 after the medical technology company delivered Q2 earnings that substantially exceeded analyst forecasts across all key metrics
1
. The adjusted loss per share came in at -$0.07, beating the consensus estimate of -$0.19 by $0.12, while quarterly revenue of $64.1 million crushed the FactSet estimate of $56.6 million4
. This represents a 48% jump from the same period a year ago, with domestic revenue alone climbing 51% year-over-year to $59.6 million1
. The company's AI-powered diagnostics platform continues to gain traction in the cardiac diagnostics market, demonstrating the growing clinical adoption of its non-invasive solutions for diagnosing and managing coronary artery disease.HeartFlow Platform Drives Revenue Growth Through AI-Driven Analyses
The HeartFlow Platform has pioneered the use of artificial intelligence and advanced computational fluid dynamics to create personalized 3D models of patients' hearts based on a single coronary computed tomography angiography, or CCTA scans
2
. The platform's three core offerings—FFRCT Analysis, Plaque Analysis, and Roadmap Analysis—work together to deliver precision care for patients with coronary artery disease5
. FFRCT Analysis and Plaque Analysis assist physicians in diagnosing and managing patients, while Roadmap Analysis offers an intuitive anatomic visualization of the coronary arteries, helping physicians quickly identify clinically relevant areas to focus their review3
. The accelerating revenue growth signals that healthcare providers are increasingly embracing these AI-driven analyses as alternatives to invasive diagnostic procedures.Management Raises Full-Year 2026 Revenue Guidance
Compounding the earnings beat, management raised its full-year 2026 revenue guidance to a range of $246 million to $250 million, a meaningful step up from the prior outlook set after a strong first quarter
1
. This marks the second consecutive quarter in which Heartflow has beaten estimates and lifted guidance, a pattern that has materially strengthened investor conviction in HTFL1
. The raised revenue guidance reflects growing confidence in the continued adoption of the Plaque Analysis platform and core FFRCT business, suggesting the company sees sustained momentum in physician uptake and patient volumes. For investors tracking the medical technology company, the guidance increase offers visibility into the durability of growth as Heartflow scales its commercial operations.Related Stories
Market Context and Competitive Positioning
The broader U.S. equity market provided virtually no tailwind on the day, with the S&P 500 adding just 0.05%, the Dow Jones edging up 0.04%, and the NASDAQ gaining 0.08%, underscoring that the sharp move in HTFL was almost entirely a company-specific event
1
. The surge propelled HTFL well above its session-day high of $31.72 and back toward the upper portion of its 52-week range of $20.13 to $41.221
. Heartflow's key competitor in the AI cardiac space, Cleerly, against whom Heartflow filed a patent infringement suit earlier this year, did not release any material news that contributed to the move1
. On the insider front, CEO John Farquhar sold approximately 22,562 shares on August 10 under a pre-scheduled Rule 10b5-1 plan, a routine, non-discretionary transaction that the market largely set aside in light of the earnings strength1
. The combination of a substantial earnings beat, accelerating revenue growth, and raised full-year outlook delivered precisely the kind of positive surprise that can trigger outsized after-hours moves in a high-growth medical technology name focused on AI-powered diagnostics for coronary artery disease.References
Summarized by
Navi
[1]
[2]
[3]
[4]
Related Stories
Heartflow's Successful IPO: AI-Driven Medtech Firm Valued at $2.27 Billion in Nasdaq Debut
08 Aug 2025•Business and Economy
HeartBeam's AI-Powered ECG Device Receives FDA Clearance for At-Home Arrhythmia Assessment
17 Dec 2024•Health
HeartSciences' MyoVista wavECG Shows Promise in Improving Heart Disease Detection
26 Jul 2024
Recent Highlights
1
AI Agents Escape Safety Tests, Start Turf Wars and Hack Real Systems in Alarming Security Incidents
Technology
2
OpenAI halts Astra AI model development over critical cybersecurity threshold concerns
Technology
3
Meta AI Pivots Strategy Again as Mark Zuckerberg Releases Muse Glimmer and 6,500-Word AI Manifesto
Technology
Recent Highlights
Today's Top Stories
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Follow topics that matter to you and stay ahead.
